Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Stem Cellx Europe Kft operates a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company currently has 1 pending office action. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. These metrics indicate a focused prosecution effort within a single technical domain. The company does not currently have a large volume of active cases or a wide distribution of examiners. This concentration suggests a highly specialized focus for the company's current research and development filings.
The busiest examiner for the portfolio is ZHU, JIANJIAN, who is handling 1 pending office action. This examiner is responsible for 1 busiest examiner pending case, which is the only pending action for the company. This means that ZHU, JIANJIAN is the sole official currently reviewing the company's patent applications. The involvement of 1 distinct art unit suggests that the technical subject matter is being evaluated by 1 specialized group. This concentration allows for a consistent prosecution narrative but also creates a single point of dependency for the company's patent goals. The focus on 1 distinct examiner simplifies the tracking of examiner-specific behavior and preferences, allowing for more targeted legal responses.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284831 | PROCESS FOR MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS IN A SUBJECT | ZHU, JIANJIAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18284831 | PROCESS FOR MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS IN A SUBJECT | ZHU, JIANJIAN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18284831 | PROCESS FOR MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOARTHRITIS IN A SUBJECT | ZHU, JIANJIAN | 1631 | §101§102§112 | Final Rejection | — | Pending | Sep 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialStem Cellx Europe Kft has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jianjian Zhu has the most, with 1 of Stem Cellx Europe Kft's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
